When a Pathology Report Says Cancer, Should the Slides Be Read Again?

What re-reading the slides actually means

Re-reading the slides means a second pathologist looks at the actual tissue — the glass slides made from your biopsy, and sometimes the paraffin tissue blocks they were cut from — rather than only re-reading the typed report. This matters because the diagnosis lives in the tissue, not the words. A records-based second opinion reviews the report and the plan; a true pathology re-read re-examines the specimen itself and can reach a different conclusion.

The physical logistics — how the slides and blocks are released, who ships them, and how they come back — are their own subject, and getting your pathology slides for review is covered separately. What follows is the clinical question underneath it: when is a re-read worth requesting at all?

How often does a re-read change the diagnosis?

For most cancer diagnoses, a re-read confirms the original. In a landmark review of 6,171 outside cases re-examined at a single referral hospital, a change of major clinical importance — one that altered treatment or prognosis — occurred in 1.4% 1Ref 1Kronz JD, Westra WH, Epstein JI (1999).Mandatory second opinion surgical pathology at a large referral hospital.That mandatory re-review of outside slides catches major, care-changing diagnostic errors at a low but consequential rate — 86 of 6,171 cases (1.4%) had a changed diagnosis of major clinical importance.. A later analysis of 4,239 second-opinion cases found major discordance in about 1.0%, and also showed how sharply the rate varies by specimen type 2Ref 2Farooq A, et al. (2021).Assessing the value of second opinion pathology review.The low-single-digit rate of management-changing pathology discordance (1.0% of 4,239 cases) and subspecialty variation, with thyroid fine-needle aspiration highest at 15.3%.. Across all diagnoses, only about 1 to 2 in 100 routine re-reads change management — but that average hides wide variation.

That same larger analysis found the highest discordance in thyroid fine-needle aspiration, at 15.3% 2Ref 2Farooq A, et al. (2021).Assessing the value of second opinion pathology review.The low-single-digit rate of management-changing pathology discordance (1.0% of 4,239 cases) and subspecialty variation, with thyroid fine-needle aspiration highest at 15.3%.. An average across every diagnosis tells you very little about your particular one, which is why the question is never simply how often re-reads change — it is how often they change for the diagnosis in front of you.

Where a re-read has the highest yield

The yield of a re-read depends almost entirely on how hard the diagnosis is to make. Clear-cut invasive cancers show high agreement between pathologists; borderline and rare specimens do not. Interpreting breast biopsies, one study found agreement with an expert reference was excellent for invasive cancer but fell to 48% for atypia — with cases both over- and under-called — and 84% for ductal carcinoma in situ 3Ref 3Elmore JG, Longton GM, Carney PA, Geller BM, Onega T, Tosteson ANA, Nelson HD, Pepe MS, Allison KH, Schnitt SJ, O'Malley FP, Weaver DL (2015).Diagnostic Concordance Among Pathologists Interpreting Breast Biopsy Specimens.That pathologist interpretation of borderline breast lesions varies substantially: agreement with an expert reference was 48% for atypia and 84% for DCIS, versus high agreement for invasive cancer.. Borderline breast lesions are among the most reinterpreted diagnoses in pathology.

Rare cancers behave the same way. Expert re-review of lymphoma diagnoses produced a major revision in roughly one in six cases, and discrepancy ranged from about 10% for Hodgkin lymphoma to as high as 75% for Burkitt lymphoma 4Ref 4Matasar MJ, Shi W, Silberstien J, et al. (2012).Expert second-opinion pathology review of lymphoma in the era of the World Health Organization classification.That expert lymphoma pathology review produces frequent, clinically meaningful revision — major revision in roughly one in six cases, with discrepancy ranging from about 10% (Hodgkin) to 75% (Burkitt).. The pattern is consistent: the rarer or more borderline the diagnosis, the more a second read can change. A lymphoma second opinion, in particular, is widely treated as standard rather than optional.

When a re-read is most worth requesting

A re-read is most worth requesting when several conditions line up. Pathologists themselves lean toward second review in exactly these situations, and it is reasonable to ask about it when:

• The diagnosis is rare, or a rare subtype is in question.
• The report hedges — phrases like 'cannot exclude,' 'suspicious for,' or 'consistent with' signal genuine uncertainty.
• The finding is borderline: atypia, in situ versus invasive, or a grade that sits on a treatment threshold.
• The diagnosis is about to drive major, hard-to-reverse treatment such as surgery, chemotherapy, or radiation.
• The original read came from a general pathology lab rather than a subspecialist who focuses on that organ.

Grading calls that steer treatment are a common trigger — prostate cancer grading and the reading of a pigmented skin lesion among them — and each of those is covered separately, because a single-step change in grade can move a person across a treatment line.

How re-reads happen

Re-reads are usually arranged through hospital pathology departments and academic consultation services. Many academic pathology departments run formal second-opinion services in which slides and reports are submitted for subspecialty re-review 5Ref 5Johns Hopkins Pathology (2025).Get a Second Opinion — Johns Hopkins Pathology.That academic pathology departments offer formal second-opinion consultation services in which slides and reports are submitted for expert subspecialty re-review.. Seeking one is a normal, expected part of cancer care, and most physicians support it; patients are also entitled to copies of their records and pathology materials 6Ref 6American Cancer Society (2024).Seeking a Second Opinion.That seeking a second opinion is a normal, expected part of cancer care that most doctors support, and that patients are entitled to copies of their records and pathology materials..

In practice, your treating oncologist or surgeon can often arrange the re-read as part of planning, or you can request it yourself before a major treatment decision. Asking does not offend a competent pathologist — re-review is a routine, built-in safeguard in cancer medicine, not a challenge to anyone's skill.

Does it matter who re-reads the slides?

It does. The value of a re-read comes largely from routing the slides to a pathologist who subspecialises in that organ or tumour type — a breast pathologist for a breast biopsy, a hematopathologist for a suspected lymphoma. The wide swings in agreement seen for borderline and rare specimens are exactly the cases where subspecialty expertise changes the reading most, while a general pathologist may encounter a given rare entity only a handful of times in a career.

This is why re-reads are usually arranged through academic or subspecialty centres rather than simply a second general lab. When requesting one, it is reasonable to ask that the case go to a pathologist who focuses on the specific diagnosis in question. For a straightforward, common cancer, a general re-read is often enough; for anything rare, borderline, or about to drive major treatment, subspecialty review is where the yield lives.

What a re-read cannot do

A re-read has limits worth understanding before requesting one. A second pathologist interprets the same tissue on the same slides, so the review is only as complete as the sample itself. If the original biopsy captured too little tissue, or missed the key area, a re-read may reach the same uncertain answer — and the honest recommendation may be a repeat biopsy rather than another opinion on the existing material.

A re-read also takes time, usually one to a few weeks depending on how quickly the slides move between labs. For most cancers that interval is safe, but it is worth confirming with the treating clinician that a short wait to confirm the diagnosis does not compromise the treatment timeline.